Promising targets in rectal cancer included carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5, referred to CEA), epithelial cell adhesion molecule (EpCAM), urokinase-type plasminogen activator receptor (uPAR) and αvβ6 integrin. Here, EPCAM is linked to rectal cancer.